EW stock forecast, quote, news & analysis
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease... Show more
Edwards Lifesciences (EW) Stock Analysis: TAVR Momentum and FDA Approvals Anchor the Growth Story
Key Takeaways
- EW advanced roughly 8% over the trailing 30 days, rising from a close of $85.15 on Oct. 2 to $92.01 on Oct. 30 — a moderate gain that stayed below the 10% threshold.
- Shares trended higher through October, supported by second-quarter results that beat expectations and raised full-year sales guidance.
- Recent FDA approvals for the PASCAL Precision tricuspid repair system and the AUTUS pediatric pulmonary valve expanded the company's structural heart portfolio.
- Wall Street remains broadly constructive, with a Strong Buy consensus rating and an average price target near $104.
- Third-quarter 2026 results are due after the close on Nov. 4, with management guiding to $1.63–$1.71 billion in sales and adjusted EPS of $0.71–$0.77.
- For additional detail, review Edwards Lifesciences' Price Targets, Earnings, and Forecast pages to track analyst expectations and forward-looking estimates.
- Explore Trending AI Robots to see how AI-driven trading strategies are monitoring EW and comparable tickers.
Current Market Snapshot
Edwards Lifesciences has traded with an upward bias over the past month, recovering from a low near $82 in early October to close at $92.01 on Oct. 30. The advance reflects a gradual, constructive move rather than a sharp, single-catalyst spike, with the stock building through the second half of October on a series of regulatory approvals and positive analyst commentary.
Sentiment toward the medical device sector has remained supportive, and Edwards sits at the center of the structural heart theme as a leading developer of transcatheter valve replacement and repair technologies. The company's market capitalization stands above $50 billion, positioning it as one of the largest pure-play cardiovascular device makers. Investor attention has centered on durable TAVR demand, rapid growth in mitral and tricuspid therapies, and an expanding pipeline of clinical data.
Edwards Lifesciences (EW) Business Overview and Competitive Position
Edwards Lifesciences Corporation designs, manufactures, and markets medical technologies focused on structural heart disease and critical care monitoring. Its core franchise is Transcatheter Aortic Valve Replacement (TAVR), anchored by the SAPIEN platform and the SAPIEN 3 Ultra RESILIA valve, which treats aortic stenosis through minimally invasive procedures. The company also operates a fast-growing Transcatheter Mitral and Tricuspid Therapies (TMTT) business built around the PASCAL Precision repair system, alongside surgical structural heart products and hemodynamic monitoring solutions.
Edwards' competitive strength stems from its leadership in TAVR, a large and still underpenetrated market, combined with a broad clinical-evidence base and a diversified pipeline across aortic, mitral, and tricuspid indications. The company generates the majority of its revenue in the United States, with substantial international exposure in Europe and Japan. Investors follow the stock closely because structural heart procedures represent a long-term, demographics-driven growth opportunity, and Edwards' execution, margin profile, and innovation cadence directly shape the investment narrative.
Recent Developments Driving EW
Several verified developments shaped the stock over the past 30 days. On Oct. 1, Edwards received FDA approval for the AUTUS Size-Adjustable Valve, the first surgical pulmonary valve designed specifically for pediatric patients with congenital heart disease. On Oct. 21, the FDA approved the PASCAL Precision system for tricuspid valve repair, while PASCAL Ace with Capture Clarity received clearance to simplify mitral transcatheter edge-to-edge repair procedures. These approvals extended the addressable market for the company's TMTT franchise.
Analyst activity was broadly supportive. Citi opened a 90-day "upside catalyst watch" while maintaining a Buy rating and $110 price target, and Barclays, UBS, and BTIG each reiterated Buy ratings with $110 targets. Other firms, including Leerink Partners and Evercore ISI, raised targets modestly, while Baird lowered its target to $90. The consensus view remained a Strong Buy with an average target near $104.
Near-term pressure also emerged: in mid-October, shares dipped following an FDA alert tied to a recall of certain Commander M delivery systems, linked to balloon bursts. The company also scheduled an investor event around the TCT 2026 scientific symposium, with market participants anticipating data from the PROGRESS trial in moderate aortic stenosis. Against this backdrop, the stock's overall trajectory remained positive into month-end.
Trending AI Robots
Tickeron's Trending AI Robots page showcases a curated selection of AI-powered trading bots. Tickeron offers hundreds of automated trading bots that monitor thousands of tickers, but only the top-performing and most relevant strategies appear in this section, making it a useful starting point for traders evaluating algorithmic approaches. The featured bots vary widely in strategy, holding timeframe, and performance metrics, allowing investors to compare different styles of automated analysis. For those interested in how quantitative, AI-driven systems are approaching equities such as Edwards Lifesciences, the page offers a practical window into current algorithmic trading activity.
2026 Outlook and What Investors Should Watch
Looking ahead, the most important near-term catalyst is Edwards' third-quarter 2026 earnings report, scheduled for after the market close on Nov. 4. Management guided to third-quarter sales of $1.63 billion to $1.71 billion and adjusted EPS of $0.71 to $0.77, and investors will assess whether TAVR and TMTT momentum continues against a strong second-quarter baseline. For the full year, Edwards has guided to sales of $6.6 billion to $6.9 billion, TAVR sales of $4.75 billion to $5.0 billion, TMTT sales of $760 million to $780 million, and adjusted EPS of $2.95 to $3.05.
Beyond earnings, several themes warrant monitoring. Clinical data from the TCT 2026 meeting, including PROGRESS trial results in moderate aortic stenosis, could influence the long-term TAVR growth outlook. Regulatory decisions and the pending national coverage determination for TAVR may shape procedural adoption in the United States. Macroeconomic factors such as foreign exchange, tax policy, and hospital procedure volumes also remain relevant, while competitive dynamics in structural heart and any further product-safety updates could affect sentiment. Investors should weigh these drivers against the company's execution rather than relying on any single data point.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
EW in upward trend: price rose above 50-day moving average on October 21, 2026
EW moved above its 50-day moving average on October 21, 2026 date and that indicates a change from a downward trend to an upward trend. In 33 of 46 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 72%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 20, 2026. You may want to consider a long position or call options on EW as a result. In 59 of 87 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 68%.
The Moving Average Convergence Divergence (MACD) for EW just turned positive on October 14, 2026. Looking at past instances where EW's MACD turned positive, the stock continued to rise in 26 of 43 cases over the following month. The odds of a continued upward trend are 60%.
The 10-day moving average for EW crossed bullishly above the 50-day moving average on October 27, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 10 of 17 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 59%.
Following a +3.86% 3-day Advance, the price is estimated to grow further. Considering data from situations where EW advanced for three days, in 172 of 289 cases, the price rose further within the following month. The odds of a continued upward trend are 60%.
The Aroon Indicator entered an Uptrend today. In 113 of 224 cases where EW Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 50%.
Bearish Trend Analysis
The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 4 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 18 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
EW broke above its upper Bollinger Band on November 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 8 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 10 (best 1 - 100 worst), indicating outstanding price growth. EW’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 72 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Seasonality Score of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 89 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.545) is normal, around the industry mean (4.142). P/E Ratio (58.701) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (1.852) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (7.974) is also within normal values, averaging (40.124).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. EW’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of products to treat late-stage cardiovascular disease
Industry MedicalNursingServices